BioSpace News Archive

Aphena Pharma Solutions Inc. today announced that it has acquired an additional 54,000-square-foot facility adjoining its current 110,000-square-foot facility in Easton, Md.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that it will begin screening its library of novel reactive aldehyde species (RASP) inhibitors, including ADX-629 and reproxalap, for potential anti-inflammatory and antiviral activity in the treatment of COVID-19 infection.

NANO-X IMAGING LTD (“Nanox” or the “Company”), an innovative medical imaging company, announces its collaboration with CureMetrix®, a global healthcare technology company that develops AI-driven software for radiology, to integrate the CureMetrix advanced AI diagnostics solution into Nanox’s planned cloud-based software platform, the Nanox.CLOUD.

Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that multiple client sites are already using its new COVID-19 Solutions announced last week, well ahead of the anticipated March 31 launch.

OncoQuest Inc. announced the publication of two reports relating to the recently completed Phase 2 trial conducted in the US and Italy utilizing oregovomab, the Company’s lead investigational drug in frontline ovarian cancer.

Ampio Pharmaceuticals, Inc. announced that it is preparing an expanded access FDA protocol to study potential benefit of nebulized treatment with Ampion in SARS-Cov-2 induced Acute Respiratory Distress Syndrome, an immediately life-threatening condition.

EUCRISA is the first and only 100% steroid-free, topical prescription medication approved for patients as young as 3 months of age in the United States

Microbix Biosystems Inc. announces the appointment of The Medical Supply Company of Ireland as a distributor.

Origin, Inc. announced that it has filed a provisional U.S. patent application to enhance the ability of its plasma-generated nitric oxide antimicrobial and antiviral therapy to be used to treat infections in the respiratory tract and other enclosed spaces in the body.

Prevail Therapeutics Inc. announced that the U.S. Food and Drug Administration has granted Fast Track Designation for the Company’s experimental gene therapy program, PR006, to slow the progression of frontotemporal dementia with a GRN mutation.